Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) have been given a consensus recommendation of “Buy” by the eight ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $13.42.

A number of research firms recently weighed in on BLCM. ValuEngine raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 10th. BidaskClub raised shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. Finally, Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research report on Friday, November 9th.

In related news, Director Jon P. Stonehouse acquired 10,000 shares of the stock in a transaction that occurred on Friday, November 9th. The stock was purchased at an average price of $4.56 per share, with a total value of $45,600.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $45,600. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 9.84% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Bellicum Pharmaceuticals by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,947,842 shares of the biopharmaceutical company’s stock valued at $11,999,000 after buying an additional 23,410 shares during the period. Jefferies Group LLC boosted its position in Bellicum Pharmaceuticals by 117.9% in the 3rd quarter. Jefferies Group LLC now owns 46,799 shares of the biopharmaceutical company’s stock valued at $288,000 after buying an additional 25,325 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Bellicum Pharmaceuticals in the 3rd quarter valued at approximately $110,000. JPMorgan Chase & Co. boosted its position in Bellicum Pharmaceuticals by 8.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,874,395 shares of the biopharmaceutical company’s stock valued at $23,866,000 after buying an additional 300,816 shares during the period. Finally, Bridgeway Capital Management Inc. boosted its position in Bellicum Pharmaceuticals by 202.0% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 149,500 shares of the biopharmaceutical company’s stock valued at $921,000 after buying an additional 100,000 shares during the period. 56.13% of the stock is owned by institutional investors.

BLCM stock traded down $0.22 during mid-day trading on Monday, reaching $4.04. The company’s stock had a trading volume of 384,045 shares, compared to its average volume of 473,545. The company has a market cap of $184.72 million, a price-to-earnings ratio of -1.42 and a beta of 1.10. The company has a current ratio of 8.01, a quick ratio of 8.01 and a debt-to-equity ratio of 0.39. Bellicum Pharmaceuticals has a fifty-two week low of $3.88 and a fifty-two week high of $10.26.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.03. The business had revenue of $0.29 million during the quarter, compared to analyst estimates of $0.07 million. As a group, equities analysts forecast that Bellicum Pharmaceuticals will post -2.39 earnings per share for the current year.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.

See Also: What is a bull market?

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.